ArticleChinese herbal medicines2025
Unveiling bioactive components in
Article in Chinese herbal medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the global mosaic of medicinal plant databases: unveiling nature's pharmacopoeia.Natural products and bioprospecting · 2026Review
- ZhiXiaoSanZheng formula ameliorates podocyte injury in diabetic kidney disease by inhibiting ferroptosis: integrated network pharmacology and experimental validation.Chinese medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Methods: SF from different origins and botanical parts were collected for integrated phytochemical analyses using ultra-high performance liquid chromatography-tandem quadrupole time of flight mass spectrometry (UPLC-Q-TOF-MS), mass spectral molecular networking and liquid chromatography-single quadrupole mass spectrometry (LC-MSD), etc., followed by the systematic chemical profile evaluation. Subsequently, the glycolipid metabolism regulation and anticoagulation of SF were examined. Furthermore, the overall information acquired was assembled using multivariate analysis and machine learning to discover bioactive components. Results: A total of 123 compounds in SF were identified with the assistance of mass spectral molecular networking. The variations in the content of amino acids, fucoidan, alginate, phlorotannin, alkaloids, terpenoids, etc. were observed in SF from different origins and botanical parts. SF possessed the hypolipidemic, hypoglycemic and anticoagulant effects, and SF from Dongtou, Wenzhou, Zhejiang, was outstanding among origins in both phytochemical and biological evaluations. A heterogeneous information ensemble approach was adopted to discover the bioactive components in SF, namely 3-indoleacrylic acid, phlorotannin and fucoidan. Conclusion: This study evaluated the phytochemical and biological properties of SF, revealed the bioactive components using heterogeneous information and provided a reference for the rational consumption and further development of SF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.